NDAINTRAVENOUSSOLUTION
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ROCURONIUM BROMIDE (rocuronium bromide) by Fresenius Kabi is duration. First approved in 2025.
Drug data last refreshed 14h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rocuronium bromide is a neuromuscular blocking agent administered intravenously as a solution. It works by competing for cholinergic receptors at the motor end-plate, with effects antagonized by acetylcholinesterase inhibitors such as neostigmine and edrophonium. This agent is used perioperatively to facilitate intubation and maintain muscle relaxation during anesthesia.
Launch
Recent launch with moderate competitive pressure (30%) suggests active commercial buildout and field team expansion opportunities.
Mechanism of Action
duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)
Started Oct 2004
149 enrolled
Anesthesia
Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)
Started Mar 2004
174 enrolled
Anesthesia, General
Career Relevance
This is a launch-phase generic/branded neuromuscular agent with moderate competitive intensity; career opportunities lie in field sales, distribution partnerships, and hospital/OR channel management. The zero linked job count suggests the market is still forming or data is incomplete, but typical launch roles in specialty hospital products will emerge.
Worked on ROCURONIUM BROMIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.